TN2011000161A1 - Fgf21 mutants and uses thereof - Google Patents
Fgf21 mutants and uses thereofInfo
- Publication number
- TN2011000161A1 TN2011000161A1 TN2011000161A TN2011000161A TN2011000161A1 TN 2011000161 A1 TN2011000161 A1 TN 2011000161A1 TN 2011000161 A TN2011000161 A TN 2011000161A TN 2011000161 A TN2011000161 A TN 2011000161A TN 2011000161 A1 TN2011000161 A1 TN 2011000161A1
- Authority
- TN
- Tunisia
- Prior art keywords
- fgf21 mutant
- polypeptides
- fgf21 mutants
- mutant polypeptides
- pharmaceutical compositions
- Prior art date
Links
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 title abstract 4
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 title abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000030159 metabolic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19576108P | 2008-10-10 | 2008-10-10 | |
| PCT/US2009/060045 WO2010042747A2 (fr) | 2008-10-10 | 2009-10-08 | Mutants fgf21 et leurs utilisations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2011000161A1 true TN2011000161A1 (en) | 2012-12-17 |
Family
ID=41571715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TN2011000161A TN2011000161A1 (en) | 2008-10-10 | 2011-04-06 | Fgf21 mutants and uses thereof |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9279013B2 (fr) |
| EP (1) | EP2358749B1 (fr) |
| JP (2) | JP5878757B2 (fr) |
| KR (1) | KR101651703B1 (fr) |
| CN (1) | CN102625811B (fr) |
| AU (1) | AU2009302318A1 (fr) |
| CA (1) | CA2739615C (fr) |
| CL (1) | CL2011000792A1 (fr) |
| CO (1) | CO6362020A2 (fr) |
| CR (1) | CR20110245A (fr) |
| EA (2) | EA201990619A1 (fr) |
| IL (1) | IL212061A0 (fr) |
| MA (1) | MA32771B1 (fr) |
| MX (1) | MX341149B (fr) |
| NZ (1) | NZ592009A (fr) |
| PE (1) | PE20120021A1 (fr) |
| SG (1) | SG195542A1 (fr) |
| TN (1) | TN2011000161A1 (fr) |
| UA (1) | UA105016C2 (fr) |
| WO (1) | WO2010042747A2 (fr) |
| ZA (1) | ZA201103356B (fr) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
| CN107501407B (zh) | 2007-03-30 | 2022-03-18 | Ambrx公司 | 经修饰fgf-21多肽和其用途 |
| TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
| US8420088B2 (en) | 2008-01-28 | 2013-04-16 | Novartis Ag | Methods and compositions using FGF23 fusion polypeptides |
| JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| JP5878757B2 (ja) * | 2008-10-10 | 2016-03-08 | アムジエン・インコーポレーテツド | Ｆｇｆ２１変異体およびその使用 |
| MX2011007544A (es) | 2009-01-23 | 2011-08-12 | Novo Nordisk As | Derivados de factor de crecimiento de fibroblastos 21 (fgf21) con ligante de albumina a-b-c-d-e- y su uso. |
| US20110195077A1 (en) * | 2010-01-29 | 2011-08-11 | Novartis Ag | Methods and compositions using fgf23 fusion ppolypeptides |
| JP2013533227A (ja) * | 2010-06-08 | 2013-08-22 | ノヴォ ノルディスク アー／エス | Ｆｇｆ２１類似体および誘導体 |
| CN103124562A (zh) * | 2010-06-08 | 2013-05-29 | 诺沃—诺迪斯克有限公司 | Fgf21的类似物和衍生物 |
| US9655974B2 (en) | 2010-07-20 | 2017-05-23 | Novo Nordisk A/S | N-terminal modified FGF21 compounds |
| MX2013002208A (es) | 2010-08-23 | 2013-05-30 | Amgen Inc | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. |
| US9023791B2 (en) * | 2010-11-19 | 2015-05-05 | Novartis Ag | Fibroblast growth factor 21 mutations |
| CN103717586A (zh) | 2011-04-05 | 2014-04-09 | 安姆根有限公司 | 用于治疗糖尿病的与葡糖激酶调节蛋白相互作用的苯并二氧杂*和苯并二氧杂环己烯化合物 |
| DK2710035T3 (en) | 2011-05-16 | 2017-06-19 | Hoffmann La Roche | FGFR1 agonists and methods of use |
| HUE045629T2 (hu) | 2011-07-01 | 2020-01-28 | Ngm Biopharmaceuticals Inc | Készítmények, alkalmazások és eljárások anyagcsere rendellenességek és betegségek kezelésére |
| CA2845357A1 (fr) * | 2011-08-31 | 2013-03-07 | Amgen Inc. | Procede de traitement ou d'amelioration du diabete de type i employant fgf21 |
| UY34347A (es) | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de función dual para tratar trastornos metabólicos |
| CN108103069B (zh) | 2012-02-15 | 2021-08-10 | 诺和诺德股份有限公司 | 结合并阻断髓样细胞表达的触发受体-1 (trem-1)的抗体 |
| US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
| EP3456742A1 (fr) | 2012-02-15 | 2019-03-20 | Novo Nordisk A/S | Anticorps qui se lient à la protéine 1 de reconnaissance du peptidoglycane |
| WO2013123444A1 (fr) | 2012-02-17 | 2013-08-22 | Amgen Inc. | Composés de sulfonyle qui interagissent avec la protéine régulatrice de la glucokinase |
| WO2013173382A1 (fr) | 2012-05-15 | 2013-11-21 | Amgen Inc. | Benzothiophène sulfonamides et autres composés qui interagissent avec une protéine régulatrice de la glucokinase |
| JP6181752B2 (ja) | 2012-06-11 | 2017-08-16 | イーライ リリー アンド カンパニー | 線維芽細胞増殖因子２１変異体 |
| TWI513705B (zh) | 2012-06-11 | 2015-12-21 | Lilly Co Eli | 纖維母細胞生長因子２１蛋白質 |
| CA2892152A1 (fr) | 2012-11-28 | 2014-06-05 | Ngm Biopharmaceuticals, Inc. | Compositions et methodes de traitement de troubles et maladies metaboliques |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| SG10202100667SA (en) | 2012-12-27 | 2021-02-25 | Ngm Biopharmaceuticals Inc | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| WO2014149699A1 (fr) | 2013-03-15 | 2014-09-25 | Eli Lilly And Company | Protéine bifonctionnelle |
| RU2707531C2 (ru) | 2013-10-28 | 2019-11-27 | ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. | Модели рака и соответствующие способы |
| TWI728373B (zh) | 2013-12-23 | 2021-05-21 | 美商建南德克公司 | 抗體及使用方法 |
| WO2015103782A1 (fr) * | 2014-01-13 | 2015-07-16 | Wenzhou Medical College Biological Pharmaceuticals And Nature Products Ltd., Co | Mutant fgf21 et son conjugué |
| KR102489475B1 (ko) | 2014-01-24 | 2023-01-20 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 결합 단백질 및 그의 사용 방법 |
| JP6712230B2 (ja) | 2014-03-11 | 2020-06-17 | ノバルティス アーゲー | リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法 |
| US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
| US10456449B2 (en) | 2014-06-16 | 2019-10-29 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| DK3172232T5 (en) | 2014-07-17 | 2024-11-18 | Novo Nordisk As | Site directed mutagenesis of trem-1 antibodies for decreasing viscosity |
| RU2729161C2 (ru) | 2014-10-23 | 2020-08-04 | ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. | Фармацевтические композиции, содержащие варианты пептидов, и способы их применения |
| HUE055311T2 (hu) | 2014-10-24 | 2021-11-29 | Bristol Myers Squibb Co | Módosított FGF-21 polipeptidek és azok felhasználása |
| WO2016073855A1 (fr) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Procédés de traitement de troubles liés à l'acide biliaire et prédiction de la sensibilité clinique au traitement de troubles liés aux acides biliaires |
| AU2015356643B2 (en) | 2014-12-04 | 2019-01-24 | Novartis Ag | Methods and compositions using Klotho variant polypeptides |
| CA2972128A1 (fr) * | 2014-12-23 | 2016-06-30 | Novo Nordisk A/S | Derives de fgf21 et utilisations de ceux-ci |
| KR20160088656A (ko) | 2015-01-16 | 2016-07-26 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| WO2016179140A1 (fr) * | 2015-05-05 | 2016-11-10 | The Regents Of The University Of California | Polymères à facteur de croissance des fibroblastes, procédés de fabrication associés et leurs applications |
| US11638745B2 (en) | 2015-05-20 | 2023-05-02 | University of Pittsburgh—Of the Commonwealth Cvctom of Hierher Education | Method to improve neurologic outcomes in temperature managed patients |
| WO2017019957A2 (fr) | 2015-07-29 | 2017-02-02 | Ngm Biopharmaceuticals, Inc. | Protéines de liaison et leurs procédés d'utilisation |
| KR102668200B1 (ko) * | 2015-10-28 | 2024-05-23 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| ES2871036T3 (es) | 2015-11-09 | 2021-10-28 | Ngm Biopharmaceuticals Inc | Método para el tratamiento de trastornos relacionados con ácidos biliares |
| TW201731867A (zh) * | 2015-12-02 | 2017-09-16 | 賽諾菲公司 | Ｆｇｆ２１變異體 |
| WO2017220706A1 (fr) | 2016-06-22 | 2017-12-28 | Novo Nordisk A/S | Compositions pharmaceutiques de dérivés de fgf21 et leurs utilisations |
| CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| CN107759697B (zh) * | 2016-08-19 | 2023-03-24 | 安源医药科技（上海）有限公司 | 制备融合蛋白的方法 |
| EP3502143A4 (fr) | 2016-08-19 | 2020-07-15 | Ampsource Biopharma Shanghai Inc. | Peptide de liaison pour la construction d'une protéine de fusion |
| AU2017315459B2 (en) | 2016-08-26 | 2023-06-29 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| AU2017382038A1 (en) | 2016-12-22 | 2019-08-08 | Sanofi | FGF21 compound / GLP-1R agonist combinations with optimized activity ratio |
| KR102664780B1 (ko) | 2017-04-21 | 2024-05-13 | 주식회사유한양행 | 이중 작용 단백질 및 그의 유도체의 제조방법 |
| CN107056925B (zh) * | 2017-04-28 | 2022-01-14 | 中国科学院合肥物质科学研究院 | 人fgf21突变体、其制备方法及用途 |
| EP3678686A1 (fr) | 2017-09-08 | 2020-07-15 | Bristol-Myers Squibb Company | Facteur de croissance des fibroblastes 21 (fgf-21) modifié destiné à une utilisation dans des méthodes de traitement de la stéatohépatite non alcoolique (nash) |
| CN116098989A (zh) * | 2018-02-08 | 2023-05-12 | 广东东阳光药业有限公司 | Fgf21变体、融合蛋白及其应用 |
| AU2019248547B2 (en) | 2018-04-02 | 2025-07-17 | Bristol-Myers Squibb Company | Anti-TREM-1 antibodies and uses thereof |
| US12226451B2 (en) | 2018-07-03 | 2025-02-18 | Bristol-Myers Squibb Company | FGF-21 formulations |
| MX2022008336A (es) | 2020-01-08 | 2022-08-08 | Bristol Myers Squibb Co | Formulaciones de conjugados del factor de crecimiento de fibroblastos 21 (fgf-21). |
| US11028132B1 (en) | 2020-04-07 | 2021-06-08 | Yitzhak Rosen | Half-life optimized linker composition |
| US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
| EP4192495A1 (fr) | 2020-08-07 | 2023-06-14 | Bristol-Myers Squibb Company | Fgf21 combiné à des antagonistes de ccr2/5 pour le traitement de la fibrose |
| US20240123031A1 (en) | 2020-11-25 | 2024-04-18 | Bristol-Myers Squibb Company | Methods of treating liver diseases |
| JP2024531980A (ja) * | 2021-09-08 | 2024-09-03 | リートー ラボラトリーズ カンパニー リミテッド | Ｆｇｆ２１変異タンパク質及びその応用 |
| WO2025164663A1 (fr) * | 2024-01-29 | 2025-08-07 | 田辺三菱製薬株式会社 | Polypeptide et son utilisation |
Family Cites Families (146)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0154316B1 (fr) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Lymphokine chimiquement modifiée et son procédé de préparation |
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| CA1310924C (fr) | 1986-04-24 | 1992-12-01 | Francis P. Mccormick | Systeme d'administration d'un medicament a l'aide de particules infectieuses |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4970154A (en) | 1987-10-09 | 1990-11-13 | Baylor College Of Medicine | Method for inserting foreign genes into cells using pulsed radiofrequency |
| EP0315456B1 (fr) | 1987-11-05 | 1994-06-01 | Hybritech Incorporated | Immunoglobulines modifiées au moyen d'un polysaccharide présentant un potentiel immunogène réduit ou des cinétiques pharmacologiques améliorées |
| US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5288855A (en) | 1989-01-23 | 1994-02-22 | Farmitalia Carlo Erba | Extracellular form of the human fibroblast growth factor receptor |
| FI920027A0 (fi) | 1989-07-06 | 1992-01-03 | Univ California | Receptorer foer fibroblasttillvaextfaktorer. |
| US5676954A (en) | 1989-11-03 | 1997-10-14 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
| HU217212B (hu) | 1989-12-22 | 1999-12-28 | Applied Research Systems, ARS Holding M.V. | Endogén gének expressziójának módosítása szabályozóelemmel |
| US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
| WO1991010470A1 (fr) | 1990-01-08 | 1991-07-25 | Brown University Research Foundation | Dispositifs et procedes d'apport ameliore de facteurs actifs |
| WO1991010741A1 (fr) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation d'anticorps xenogeniques |
| US5672510A (en) | 1990-01-19 | 1997-09-30 | Genetic Therapy, Inc. | Retroviral vectors |
| DK0538404T3 (da) | 1990-07-06 | 2003-10-13 | Rhone Poulenc Rorer Internat H | Fibroblaste vækstfaktorreceptorer |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5217889A (en) | 1990-10-19 | 1993-06-08 | Roninson Igor B | Methods and applications for efficient genetic suppressor elements |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US5229501A (en) | 1991-01-11 | 1993-07-20 | Chiron Corporation | Expression and use of human fibroblast growth factor receptor |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| IL100219A0 (en) | 1991-12-02 | 1992-09-06 | Yeda Res & Dev | Variable region within fibroblast growth factor receptors that confers ligand specificity |
| WO1993015722A1 (fr) | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Liberation controlee de produits pharmaceutiques a partir de microparticules poreuses preformees |
| US5234784A (en) | 1992-04-01 | 1993-08-10 | Eastman Kodak Company | Method of making a projection viewable transparency comprising an electrostatographic toner image |
| US5364791A (en) | 1992-05-14 | 1994-11-15 | Elisabetta Vegeto | Progesterone receptor having C. terminal hormone binding domain truncations |
| CA2136439A1 (fr) | 1992-06-18 | 1994-01-06 | Michael Philip Nova | Methode de detection des maladies neoplasiques |
| AU675661B2 (en) | 1992-07-24 | 1997-02-13 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5474914A (en) | 1992-07-29 | 1995-12-12 | Chiron Corporation | Method of producing secreted CMV glycoprotein H |
| US5489743A (en) | 1993-01-19 | 1996-02-06 | Amgen Inc. | Transgenic animal models for thrombocytopenia |
| US5581476A (en) | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
| CA2162275A1 (fr) | 1993-05-07 | 1994-11-24 | Robert George Flynn | Lait et produits laitiers a lactose hydrolyse, au gout ameliore et a sucrosite reduite |
| US6664107B1 (en) | 1993-05-26 | 2003-12-16 | Ontario Cancer Institute, University Health Network | CD45 disrupted nucleic acid |
| US5654168A (en) | 1994-07-01 | 1997-08-05 | Basf Aktiengesellschaft | Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units |
| DE705334T1 (de) | 1993-06-14 | 1999-12-30 | Basf Ag | Strenge kontrolle der genexpression in eukaryotischen zellen durch auf tetrazyklin ansprechende promotoren |
| US5589362A (en) | 1993-06-14 | 1996-12-31 | Basf Aktiengesellschaft | Tetracycline regulated transcriptional modulators with altered DNA binding specificities |
| US5484720A (en) | 1994-09-08 | 1996-01-16 | Genentech, Inc. | Methods for calcium phosphate transfection |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| CN1191568A (zh) | 1995-05-26 | 1998-08-26 | 曾尼卡有限公司 | 包含蜕皮激素受体的基因开关 |
| JPH11506722A (ja) | 1995-06-07 | 1999-06-15 | ベイラー・カレッジ・オブ・メディスン | 細胞に核酸を送達するための核酸運搬体 |
| KR19990022651A (ko) | 1995-06-07 | 1999-03-25 | 데이비드 엘. 버스테인 | 생물학적 사건에 대한 라파마이신 기재 조절방법 |
| CA2244363C (fr) | 1996-02-28 | 2006-11-14 | Ariad Gene Therapeutics, Inc. | Derives synthetiques de rapamycine utilises comme agents de multimerisation de proteines chimeres a domaines derives de l'immunophiline |
| US5679559A (en) | 1996-07-03 | 1997-10-21 | University Of Utah Research Foundation | Cationic polymer and lipoprotein-containing system for gene delivery |
| US6214795B1 (en) | 1996-11-12 | 2001-04-10 | Praecis Pharmaceuticals, Inc. | Peptide compounds useful for modulating FGF receptor activity |
| EP0945506B1 (fr) | 1996-12-26 | 2007-02-28 | Kyowa Hakko Kogyo Co., Ltd. | Protein mit der eigenschaft das altern zu unterdrücken |
| US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| US6150098A (en) | 1998-02-20 | 2000-11-21 | Amgen Inc. | Methods for identifying novel secreted mammalian polypeptides |
| ZA200007412B (en) | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
| US6548634B1 (en) | 1998-09-30 | 2003-04-15 | Chiron Corporation | Synthetic peptides having FGF receptor affinity |
| WO2000027885A1 (fr) | 1998-11-05 | 2000-05-18 | Kyowa Hakko Kogyo Co., Ltd. | Nouveau popypeptide chimerique |
| US6656728B1 (en) | 1999-02-08 | 2003-12-02 | Chiron Corporation | Fibroblast growth factor receptor-immunoglobulin fusion |
| AU3755900A (en) | 1999-03-15 | 2000-10-04 | Chiron Corporation | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| CA2311201A1 (fr) | 1999-08-05 | 2001-02-05 | Genset S.A. | Sequences marqueurs exprimees et proteines humaines codees |
| US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| US7408047B1 (en) | 1999-09-07 | 2008-08-05 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| AU7368100A (en) | 1999-09-10 | 2001-04-10 | Curagen Corporation | Fibroblast growth factor polypeptide and nucleic acids encoding same |
| WO2001032678A1 (fr) | 1999-11-05 | 2001-05-10 | Smithkline Beecham Corporation | sbgFGF-19a |
| US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
| WO2001036640A2 (fr) | 1999-11-18 | 2001-05-25 | Chiron Corporation | Gene humain fgf-21 et produits d'expression genique |
| AU1628101A (en) | 1999-11-22 | 2001-06-04 | Millennium Pharmaceuticals, Inc. | Jaffa, a novel fibroblast growth factor family member and uses therefor |
| US7108984B2 (en) | 2000-01-12 | 2006-09-19 | Mount Sinai School Of Medicine | Methods of identifying modulators of the FGF receptor |
| US20020081663A1 (en) | 2000-01-05 | 2002-06-27 | Conklin Darrell C. | Novel FGF homolog ZFGF11 |
| WO2001049849A1 (fr) | 2000-01-05 | 2001-07-12 | Zymogenetics, Inc. | Zfgf11 : nouvel homologue de fgf |
| US20020001825A1 (en) | 2000-03-31 | 2002-01-03 | Nobuyuki Itoh | Fibroblast growth factor-like molecules and uses thereof |
| JP2002112772A (ja) | 2000-07-10 | 2002-04-16 | Takeda Chem Ind Ltd | 新規ポリペプチドおよびそのｄｎａ |
| IL139380A0 (en) | 2000-10-31 | 2001-11-25 | Prochon Biotech Ltd | Active variants of fibroblast growth factor |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| US20060223114A1 (en) | 2001-04-26 | 2006-10-05 | Avidia Research Institute | Protein scaffolds and uses thereof |
| US20040018499A1 (en) | 2001-06-06 | 2004-01-29 | Lal Preeti G | Extracellular messengers |
| EP1423428B2 (fr) | 2001-06-20 | 2012-11-14 | Fibron Ltd. | Anticorps bloquant l'activation de fgfr3, procedes de criblage et utilisations associes |
| EP1425304B9 (fr) | 2001-07-11 | 2010-09-08 | Maxygen, Inc. | Conjugues de g-csf |
| WO2003011213A2 (fr) | 2001-07-30 | 2003-02-13 | Eli Lilly And Company | Methode de traitement du diabete et de l'obesite |
| WO2003038054A2 (fr) | 2001-10-31 | 2003-05-08 | New York University | Conception et synthese de type structurel d'inhibiteurs de facteur de croissance fibroblastique (fgf), et composes modulateurs de fgf |
| JP2005519891A (ja) | 2002-01-15 | 2005-07-07 | イーライ・リリー・アンド・カンパニー | 危篤状態の患者における罹病率および死亡率を低下させる方法 |
| EP1332761A1 (fr) | 2002-01-31 | 2003-08-06 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Agonistes des récepteurs du facteur de croissance des fibroblastes |
| US7531304B2 (en) | 2002-01-31 | 2009-05-12 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Method for screening FGFR-4 agonists |
| IL149562A0 (en) | 2002-05-09 | 2002-11-10 | Prochon Ltd | Fgf variants and methods for use thereof |
| JP2003334088A (ja) | 2002-05-22 | 2003-11-25 | Pharma Design Inc | ヒト由来の新規Ｋｌｏｔｈｏ様タンパク質及びその遺伝子 |
| AU2003265057A1 (en) | 2002-09-04 | 2004-03-29 | Abtech | Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy |
| AU2003284357A1 (en) | 2002-11-01 | 2004-06-07 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20060281130A1 (en) | 2002-12-20 | 2006-12-14 | Elisabeth Bock | Metod of modulation of interaction between receptor and ligand |
| WO2004083381A2 (fr) | 2003-03-13 | 2004-09-30 | Indiana University Advanced Research & Technology Institute | Polynucleotides, polypeptides et mutants des recepteurs 1 du facteur de croissance des fibroblastes |
| JP2006240990A (ja) | 2003-05-15 | 2006-09-14 | Kirin Brewery Co Ltd | ｋｌｏｔｈｏタンパク質および抗ｋｌｏｔｈｏタンパク質抗体ならびにそれらの用途 |
| ES2298785T3 (es) | 2003-06-12 | 2008-05-16 | Eli Lilly And Company | Proteinas de fusion. |
| PL1641823T3 (pl) | 2003-06-12 | 2012-02-29 | Lilly Co Eli | Białka fuzyjne analogu GLP-1 |
| WO2005019258A2 (fr) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions et methodes de traitement de maladies relatives au systeme immunitaire |
| EP1680140B1 (fr) | 2003-10-16 | 2011-04-20 | Imclone LLC | Inhibiteurs du recepteur 1 du facteur de croissance du fibroblaste et methodes therapeutiques associees |
| EA200601121A1 (ru) * | 2003-12-10 | 2006-10-27 | Эли Лилли Энд Компани | Мутеины фактора роста фибробластов 21 |
| CA2550245A1 (fr) | 2003-12-19 | 2005-07-21 | Five Prime Therapeutics, Inc. | Utilisation des recepteurs 1, 2, 3 et 4 du facteur de croissance des fibroblastes comme cibles pour une intervention therapeutique |
| EP1727559A1 (fr) | 2004-01-26 | 2006-12-06 | Eli Lilly And Company | Utilisation de fgf-21 et d'une thiazolidinedione pour traiter le diabete de type 2 |
| JP2007531715A (ja) * | 2004-03-17 | 2007-11-08 | イーライ リリー アンド カンパニー | グリコール結合ｆｇｆ−２１化合物 |
| JP4505631B2 (ja) | 2004-03-31 | 2010-07-21 | 独立行政法人産業技術総合研究所 | ヘパラン硫酸糖鎖を付加したヘパリン結合性タンパク質、その製造方法及びそれを含有する医薬組成物 |
| EP2194064A1 (fr) | 2004-05-13 | 2010-06-09 | Eli Lilly & Company | Protéines de fusion FGF-21 |
| EP1789443A1 (fr) | 2004-09-02 | 2007-05-30 | Eli Lilly And Company | Muteines du facteur de croissance 21 du fibroblaste |
| JP4809352B2 (ja) | 2004-09-02 | 2011-11-09 | イーライ リリー アンド カンパニー | 線維芽細胞成長因子２１の突然変異タンパク質 |
| US20080176790A1 (en) * | 2004-10-29 | 2008-07-24 | Defrees Shawn | Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf) |
| EP1831371A2 (fr) | 2004-12-14 | 2007-09-12 | Eli Lilly And Company | Muteines du facteur de croissance fibroblastique 21 |
| EP1846019A2 (fr) | 2005-01-21 | 2007-10-24 | Eli Lilly And Company | Methode de traitement de maladie cardio-vasculaire |
| JP2006246823A (ja) | 2005-03-11 | 2006-09-21 | Kyoto Univ | 造血因子としてのＦｇｆ２１の使用 |
| WO2006130527A2 (fr) | 2005-05-31 | 2006-12-07 | Novartis Ag | Mutations et polymorphismes de recepteur du facteur de croissance 1 des fibroblastes |
| ATE450615T1 (de) | 2005-07-22 | 2009-12-15 | Five Prime Therapeutics Inc | Zusammensetzungen und verfahren zur behandlung von krankheiten mit fgfr-fusionsproteinen |
| AU2006280321A1 (en) | 2005-08-15 | 2007-02-22 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
| WO2007055789A2 (fr) | 2005-10-31 | 2007-05-18 | Neose Technologies, Inc. | Expression de proteines therapeutiques solubles |
| AU2007221177A1 (en) | 2006-02-28 | 2007-09-07 | Trustees Of Boston University | Methods to identify factors associated with muscle growth and uses thereof |
| EP2046384A4 (fr) | 2006-06-15 | 2009-12-02 | Fibron Ltd | Anticorps bloquant l'activation du récepteur du facteur de croissance des fibroblastes et leurs procédés d'utilisation |
| US20080248959A1 (en) | 2006-07-21 | 2008-10-09 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
| WO2008057683A2 (fr) | 2006-10-03 | 2008-05-15 | Novo Nordisk A/S | Méthodes de purification de conjugués de polypeptides |
| JP2010511382A (ja) | 2006-12-01 | 2010-04-15 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | 癌関連タンパク質キナーゼ |
| CN107501407B (zh) * | 2007-03-30 | 2022-03-18 | Ambrx公司 | 经修饰fgf-21多肽和其用途 |
| EP2550972B1 (fr) | 2007-04-02 | 2018-02-21 | Genentech, Inc. | Un anticorps agoniste de Klotho-béta à utiliser dans le traitement du diabète et de la résistance à l'insuline |
| WO2008123625A1 (fr) | 2007-04-06 | 2008-10-16 | National Institute Of Advanced Industrial Science And Technology | Methode d'activation de recepteur au moyen d'un cofacteur et methode d'utilisation d'activite de ligand |
| US7537903B2 (en) | 2007-04-23 | 2009-05-26 | Board Of Regents, The University Of Texas System | FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner |
| WO2008135993A1 (fr) | 2007-05-08 | 2008-11-13 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Protéine klotho et composés apparentés destinés au traitement et au diagnostic du cancer |
| EA200901550A1 (ru) | 2007-05-22 | 2010-10-29 | Новартис Аг | Способы лечения, диагностирования и выявления ассоциированных с fgf21 нарушений |
| JP5563818B2 (ja) | 2007-05-29 | 2014-07-30 | 北海道公立大学法人 札幌医科大学 | 癌治療剤及び癌の治療方法 |
| CN101778937A (zh) | 2007-06-04 | 2010-07-14 | 诺和诺德公司 | 使用n-乙酰葡糖胺转移酶的o-联糖基化 |
| JP2010535781A (ja) | 2007-08-03 | 2010-11-25 | イーライ リリー アンド カンパニー | 肥満に対する処置 |
| US8426396B2 (en) | 2008-01-08 | 2013-04-23 | Shriners Hospitals For Children | Treatment for achondroplasia |
| TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
| WO2009117622A2 (fr) | 2008-03-19 | 2009-09-24 | Ambrx, Inc. | Polypeptides fgf-23 modifiés et leurs utilisations |
| JOP20190083A1 (ar) * | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| WO2010006214A1 (fr) | 2008-07-09 | 2010-01-14 | Ambrx, Inc. | Anticorps de neutralisation de fgf-21 et leurs utilisations |
| JP5787757B2 (ja) | 2008-08-04 | 2015-09-30 | ファイブ プライム セラピューティックス インコーポレイテッド | Ｆｇｆｒ細胞外ドメイン酸性領域突然変異タンパク質 |
| JP5878757B2 (ja) * | 2008-10-10 | 2016-03-08 | アムジエン・インコーポレーテツド | Ｆｇｆ２１変異体およびその使用 |
| JP2012525847A (ja) | 2009-05-05 | 2012-10-25 | アムジエン・インコーポレーテツド | Ｆｇｆ２１変異体およびその使用 |
| BRPI1011404B1 (pt) | 2009-05-05 | 2022-05-03 | Amgen Inc | Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira |
-
2009
- 2009-10-08 JP JP2011531178A patent/JP5878757B2/ja active Active
- 2009-10-08 EP EP09748878.7A patent/EP2358749B1/fr active Active
- 2009-10-08 CN CN200980150308.1A patent/CN102625811B/zh active Active
- 2009-10-08 PE PE2011000856A patent/PE20120021A1/es not_active Application Discontinuation
- 2009-10-08 MX MX2011003788A patent/MX341149B/es active IP Right Grant
- 2009-10-08 KR KR1020117010559A patent/KR101651703B1/ko active Active
- 2009-10-08 EA EA201990619A patent/EA201990619A1/ru unknown
- 2009-10-08 EA EA201100516A patent/EA032727B1/ru unknown
- 2009-10-08 WO PCT/US2009/060045 patent/WO2010042747A2/fr not_active Ceased
- 2009-10-08 CA CA2739615A patent/CA2739615C/fr active Active
- 2009-10-08 UA UAA201105749A patent/UA105016C2/uk unknown
- 2009-10-08 SG SG2013075916A patent/SG195542A1/en unknown
- 2009-10-08 NZ NZ592009A patent/NZ592009A/xx unknown
- 2009-10-08 US US13/123,205 patent/US9279013B2/en active Active
- 2009-10-08 AU AU2009302318A patent/AU2009302318A1/en not_active Abandoned
-
2011
- 2011-03-31 IL IL212061A patent/IL212061A0/en unknown
- 2011-04-06 TN TN2011000161A patent/TN2011000161A1/fr unknown
- 2011-04-07 CO CO11043102A patent/CO6362020A2/es not_active Application Discontinuation
- 2011-04-08 CL CL2011000792A patent/CL2011000792A1/es unknown
- 2011-05-05 MA MA33815A patent/MA32771B1/fr unknown
- 2011-05-09 ZA ZA2011/03356A patent/ZA201103356B/en unknown
- 2011-05-10 CR CR20110245A patent/CR20110245A/es unknown
-
2015
- 2015-04-02 JP JP2015075667A patent/JP2015165801A/ja active Pending
-
2016
- 2016-01-27 US US15/007,438 patent/US20160244497A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CL2011000792A1 (es) | 2011-08-26 |
| WO2010042747A3 (fr) | 2010-06-17 |
| SG195542A1 (en) | 2013-12-30 |
| CN102625811A (zh) | 2012-08-01 |
| CN102625811B (zh) | 2016-09-21 |
| JP5878757B2 (ja) | 2016-03-08 |
| NZ592009A (en) | 2012-11-30 |
| CA2739615C (fr) | 2017-12-05 |
| US20110195895A1 (en) | 2011-08-11 |
| MX2011003788A (es) | 2011-08-03 |
| JP2012504965A (ja) | 2012-03-01 |
| IL212061A0 (en) | 2011-06-30 |
| MX341149B (es) | 2016-08-09 |
| WO2010042747A2 (fr) | 2010-04-15 |
| MA32771B1 (fr) | 2011-11-01 |
| ZA201103356B (en) | 2012-02-29 |
| US20160244497A1 (en) | 2016-08-25 |
| CR20110245A (es) | 2011-08-29 |
| KR101651703B1 (ko) | 2016-08-26 |
| EA032727B1 (ru) | 2019-07-31 |
| EP2358749A2 (fr) | 2011-08-24 |
| KR20110093790A (ko) | 2011-08-18 |
| CO6362020A2 (es) | 2012-01-20 |
| EA201990619A1 (ru) | 2019-07-31 |
| AU2009302318A1 (en) | 2010-04-15 |
| JP2015165801A (ja) | 2015-09-24 |
| US9279013B2 (en) | 2016-03-08 |
| UA105016C2 (uk) | 2014-04-10 |
| EA201100516A1 (ru) | 2011-10-31 |
| EP2358749B1 (fr) | 2018-07-18 |
| CA2739615A1 (fr) | 2010-04-15 |
| PE20120021A1 (es) | 2012-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY152721A (en) | Fgf21 mutants and uses thereof | |
| TN2011000161A1 (en) | Fgf21 mutants and uses thereof | |
| PH12015502433A1 (en) | Fgf21 mutants and uses thereof | |
| WO2010129600A3 (fr) | Mutants de fgf21 et leurs utilisations | |
| MX2011013903A (es) | Polipeptidos quimericos y usos de los mismos. | |
| MX2009002816A (es) | Proteinas de fusion de albumina. | |
| PH12013501101A1 (en) | Immunosuppressive polypeptides and nucleic acids | |
| MX368459B (es) | Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central. | |
| SG170086A1 (en) | Modified molecules which promote hematopoiesis | |
| MY159491A (en) | Disubstituted phthalazine hedgehog pathway antagonists | |
| TN2011000166A1 (en) | Disubstituted phthalazine hedgehog pathway antagonists | |
| AP2011005814A0 (en) | Gene encoding human glucokinase mutant, enzyme encoded by the same, recombinant vectors and hosts, pharmaceutical compositions and uses thereof, methods for treating and preventing diseases. | |
| UA102395C2 (en) | Fgf21 mutants and use thereof | |
| TN2011000553A1 (en) | Fgf21 mutants and uses thereof | |
| TN2010000563A1 (en) | Fgf 21 mutants and uses thereof | |
| WO2008033374A3 (fr) | Compositions de ocl-2a3 et utilisations de celles-ci |